MitoChem Therapeutics
Private Company
Funding information not available
Overview
MitoChem Therapeutics is a preclinical-stage biotech targeting neurodegenerative diseases by addressing their root metabolic cause: mitochondrial dysfunction. The company's core platform is a library of mitochondrial-protective small molecules, with lead candidate MC16 designed to correct the mislocalization of the RNA-binding protein FUS, thereby restoring cellular energy balance. Its initial focus is on Amyotrophic Lateral Sclerosis (ALS) and Retinitis Pigmentosa (RP), aiming to provide mutation-agnostic therapies for these high-need indications. As a private, pre-revenue company, MitoChem is advancing its programs through preclinical proof-of-concept studies.
Technology Platform
A library of mitochondrial-protective small molecules. The platform targets protein mislocalization (specifically of FUS) and mitochondrial dysfunction to restore cellular energy metabolism in neurons and photoreceptors.
Opportunities
Risk Factors
Competitive Landscape
In ALS, competitors range from approved symptomatic drugs (riluzole, edaravone) to companies targeting other pathways (SOD1, anti-inflammatories, etc.). In RP, competition includes gene-specific therapies and neuroprotective agents. MitoChem's differentiation lies in its specific focus on FUS-driven mitochondrial dysfunction as a foundational disease mechanism.